Faraz Ali Sells 9,748 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) CEO Faraz Ali sold 9,748 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.89, for a total transaction of $28,171.72. Following the completion of the sale, the chief executive officer now directly owns 188,331 shares of the company’s stock, valued at approximately $544,276.59. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Tenaya Therapeutics Price Performance

Shares of NASDAQ:TNYA traded down $0.11 during mid-day trading on Friday, reaching $2.89. 449,025 shares of the company were exchanged, compared to its average volume of 454,665. The firm has a market cap of $226.92 million, a price-to-earnings ratio of -1.76 and a beta of 2.43. The firm’s 50-day simple moving average is $3.23 and its 200 day simple moving average is $4.28. Tenaya Therapeutics, Inc. has a 1 year low of $1.66 and a 1 year high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, research analysts forecast that Tenaya Therapeutics, Inc. will post -1.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tenaya Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TNYA. The Manufacturers Life Insurance Company boosted its position in Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after buying an additional 7,000 shares during the period. Algert Global LLC acquired a new stake in shares of Tenaya Therapeutics in the 2nd quarter valued at $74,000. SG Americas Securities LLC raised its holdings in shares of Tenaya Therapeutics by 20.0% in the 4th quarter. SG Americas Securities LLC now owns 25,337 shares of the company’s stock valued at $82,000 after purchasing an additional 4,224 shares in the last quarter. Bailard Inc. acquired a new stake in shares of Tenaya Therapeutics in the 4th quarter valued at $107,000. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Tenaya Therapeutics in the 2nd quarter valued at $164,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Analysts Set New Price Targets

TNYA has been the subject of several analyst reports. William Blair initiated coverage on shares of Tenaya Therapeutics in a research note on Monday, June 10th. They issued an “outperform” rating for the company. Canaccord Genuity Group lowered their price objective on shares of Tenaya Therapeutics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday, July 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.25.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.